1. Home
  2. HMH vs AKBA Comparison

HMH vs AKBA Comparison

Compare HMH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HMH Holding Inc. Class A Common Stock

HMH

HMH Holding Inc. Class A Common Stock

N/A

Current Price

$18.56

Market Cap

237.2M

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.71

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HMH
AKBA
Founded
2021
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil and Gas Field Machinery
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
237.2M
248.3M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
HMH
AKBA
Price
$18.56
$0.71
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
★ $28.71
$3.92
AVG Volume (30 Days)
139.6K
★ 8.4M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
★ 1.26
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.81
N/A
P/E Ratio
$14.81
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.51
$0.54
52 Week High
$22.34
$2.22

Technical Indicators

Market Signals
Indicator
HMH
AKBA
Relative Strength Index (RSI) 52.47 45.21
Support Level $18.30 $0.54
Resistance Level $20.16 $0.98
Average True Range (ATR) 0.83 0.06
MACD 0.15 0.01
Stochastic Oscillator 76.60 64.12

Price Performance

Historical Comparison
HMH
AKBA

About HMH HMH Holding Inc. Class A Common Stock

HMH Holding Inc is a provider of offshore and onshore drilling equipment and services in the United States and Norway. Its services include sales of projects and products including drilling equipment packages for newbuild or a reactivated drilling rig, and individual or grouped components of drilling and pressure control equipment. The company also offers aftermarket services including services and replacement parts on installed equipment and integrated digital solutions. The company sells equipment and services to drilling contractors; operators, including both oil and gas E&P companies and mining companies onshore and offshore; and manufacturers, consisting of shipyards.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: